The new agreement covers the supply and commercialization in Europe of biosimilar candidates to Ilaris (canakinumab), a human antibody interleukin-1β blocker indicated for the treatment of various inflammatory diseases, and Kesimpta (ofatumumab), a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis, in addition to a third undisclosed biosimilar candidate.

“We now have agreed to launch proposed biosimilars to more than ten reference products in Europe, starting in 2025 and reaching beyond 2030. This new agreement demonstrates the business development potential and value of Alvotech’s growing biosimilars pipeline, that is unrivalled by any other biosimilars developer,” says Róbert Wessman, chairman and CEO of Alvotech.

Up to USD 180 million

Alvotech will be responsible for development and commercial supply and Advanz Pharma will be responsible for registration and commercialization in Europe. The agreement includes development and commercial milestones for the three products, totaling up to USD 180 million at current exchange rates (EUR 160 million). In addition, the partners will participate in a revenue share.

A partnership agreement signed 2023

Alvotech and Advanz Pharma previously entered into partnership agreements, signed in 2023, to commercialize proposed biosimilars to Xolair (omalizumab), Simponi (golimumab), Entyvio (vedolizumab), Eylea (aflibercept) and Eylea HD (aflibercept), Dupixent (dupilumab), Taltz (ixekizumab) and Tremfya (guselkumab). The supply and commercialization agreements cover all 30 member countries of the European Economic Area, as well as the UK and Switzerland. For omalizumab, the agreement additionally includes Canada, Australia, and New Zealand.